1-3 of 3
Barbara De Moerloose
Close
Sort by
Journal Articles

Optimized cytogenetic risk-group stratification of KMT2A -rearranged pediatric acute myeloid leukemia

Romy E. van Weelderen, Christine J. Harrison, Kim Klein, Yilin Jiang, Jonas Abrahamsson, Todd Alonzo, Richard Aplenc, Nira Arad-Cohen, Emmanuelle Bart-Delabesse, Barbara Buldini, Barbara De Moerloose, Michael N. Dworzak, Sarah Elitzur, José M. Fernández Navarro, Alan Gamis, Robert B. Gerbing, Bianca F. Goemans, Hester A. de Groot-Kruseman, Erin Guest, Shau-Yin Ha, Henrik Hasle, Charikleia Kelaidi, Hélène Lapillonne, Guy Leverger, Franco Locatelli, Takako Miyamura, Ulrika Norén-Nyström, Sophia Polychronopoulou, Mareike Rasche, Jeffrey E. Rubnitz, Jan Stary, Anne Tierens, Daisuke Tomizawa, C. Michel Zwaan, Gertjan J. L. Kaspers
Journal: Blood Advances
Blood Adv (2024) 8 (12): 3200–3213.
https://doi.org/10.1182/bloodadvances.2023011771
Published: 2024
Includes: Supplemental data
Journal Articles

A 69 long noncoding RNA signature predicts relapse and acts as independent prognostic factor in pediatric AML

Zhiyao Ren, Jolien Vanhooren, Charlotte Derpoorter, Barbara De Moerloose, Tim Lammens
Journal: Blood Advances
Blood Adv (2024) 8 (12): 3299–3310.
https://doi.org/10.1182/bloodadvances.2024012667
Published: 2024
Includes: Supplemental data
Journal Articles

Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy

Jochen Buechner, Stephan A. Grupp, Hidefumi Hiramatsu, David T. Teachey, Susana Rives, Theodore W. Laetsch, Gregory A. Yanik, Patricia Wood, Rakesh Awasthi, Lan Yi, Andrea Chassot-Agostinho, Lamis K. Eldjerou, Barbara De Moerloose
Journal: Blood Advances
Blood Adv (2021) 5 (2): 593–601.
https://doi.org/10.1182/bloodadvances.2020002757
Published: 2021
Includes: Supplemental data